• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型三氟喹诺酮Ro 23-6240的药代动力学和组织穿透性

Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

作者信息

Wise R, Kirkpatrick B, Ashby J, Griggs D J

出版信息

Antimicrob Agents Chemother. 1987 Feb;31(2):161-3. doi: 10.1128/AAC.31.2.161.

DOI:10.1128/AAC.31.2.161
PMID:3105446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC174683/
Abstract

A 400-mg dose of the trifluorinated quinolone Ro 23-6240 was administered orally to each of six healthy male volunteers, after which the concentrations of this agent in serum and cantharidin-induced inflammatory fluid were measured. Absorption was rapid, with a mean peak level in serum of 6.1 micrograms/ml, which was attained 0.71 h after administration. The elimination half-life in serum was 11.95 h. The agent penetrated the inflammatory fluid rapidly; the percent penetration was 89.7%. Urinary recovery of Ro 23-6240 was 58.6% by 72 h.

摘要

给6名健康男性志愿者每人口服400毫克的三氟喹诺酮Ro 23 - 6240,之后测量该药物在血清和斑蝥素诱导的炎性液中的浓度。吸收迅速,血清中的平均峰值水平为6.1微克/毫升,给药后0.71小时达到该值。血清中的消除半衰期为11.95小时。该药物迅速渗透到炎性液中;渗透百分比为89.7%。到72小时时,Ro 23 - 6240的尿回收率为58.6%。

相似文献

1
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.新型三氟喹诺酮Ro 23-6240的药代动力学和组织穿透性
Antimicrob Agents Chemother. 1987 Feb;31(2):161-3. doi: 10.1128/AAC.31.2.161.
2
Pharmacokinetics and tissue penetration of ciprofloxacin.环丙沙星的药代动力学及组织穿透性
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
3
The pharmacokinetics and tissue penetration of norfloxacin.诺氟沙星的药代动力学及组织穿透性。
J Antimicrob Chemother. 1984 Jan;13(1):87-92. doi: 10.1093/jac/13.1.87.
4
Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.三氟喹诺酮类药物氟罗沙星在人体中的单剂量和多剂量药代动力学。
Antimicrob Agents Chemother. 1987 Dec;31(12):1909-14. doi: 10.1128/AAC.31.12.1909.
5
Pharmacokinetics and tissue penetration of enoxacin.依诺沙星的药代动力学和组织穿透性。
Antimicrob Agents Chemother. 1984 Jul;26(1):17-9. doi: 10.1128/AAC.26.1.17.
6
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.司帕沙星的药代动力学及炎性液体渗透情况
Antimicrob Agents Chemother. 1992 Nov;36(11):2444-6. doi: 10.1128/AAC.36.11.2444.
7
Pharmacokinetics and tissue penetration of orally administered pefloxacin.口服培氟沙星的药代动力学及组织穿透性
Eur J Clin Microbiol. 1987 Oct;6(5):521-4. doi: 10.1007/BF02014239.
8
The metabolism and pharmacokinetics of fleroxacin in healthy subjects.氟罗沙星在健康受试者中的代谢及药代动力学
J Antimicrob Chemother. 1988 Oct;22 Suppl D:191-4. doi: 10.1093/jac/22.supplement_d.191.
9
Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.新型三氟喹诺酮Ro 23-6240(AM 833)的药代动力学
Chemioterapia. 1987 Jun;6(2 Suppl):307-8.
10
The pharmacokinetics and tissue penetration of ofloxacin.氧氟沙星的药代动力学和组织穿透性。 (注:原文中多了一个of,正确表述应该是The pharmacokinetics and tissue penetration of ofloxacin )
J Antimicrob Chemother. 1984 Dec;14(6):647-52. doi: 10.1093/jac/14.6.647.

引用本文的文献

1
Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.通过正电子发射断层扫描研究[18F]氟罗沙星在慢性支气管炎急性加重期和复杂性尿路感染患者中的药代动力学。
Antimicrob Agents Chemother. 1996 Mar;40(3):659-64. doi: 10.1128/AAC.40.3.659.
2
Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.影响氟罗沙星消除和分布的因素:来自10项药代动力学研究的个体数据的荟萃分析。
Antimicrob Agents Chemother. 1996 Mar;40(3):575-80. doi: 10.1128/AAC.40.3.575.
3
The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.饮用牛奶对健康志愿者中氟罗沙星和环丙沙星药代动力学的影响。
Drugs. 1995;49 Suppl 2:346-8. doi: 10.2165/00003495-199500492-00094.
4
Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.利用正电子发射断层扫描研究健康人体受试者中[18F]氟罗沙星的药代动力学。
Antimicrob Agents Chemother. 1993 Oct;37(10):2144-52. doi: 10.1128/AAC.37.10.2144.
5
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.氟罗沙星。对其在各种感染中的药理学及治疗效果的综述。
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
6
Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.单次及多次服用400毫克和800毫克剂量氟罗沙星后的药代动力学及组织渗透情况。
Antimicrob Agents Chemother. 1988 Oct;32(10):1515-20. doi: 10.1128/AAC.32.10.1515.
7
Treatment of experimental Salmonella typhimurium infection in mice with fleroxacin.用氟罗沙星治疗小鼠实验性鼠伤寒沙门氏菌感染。
Antimicrob Agents Chemother. 1988 May;32(5):791-2. doi: 10.1128/AAC.32.5.791.
8
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).新型喹诺酮类药物氟罗沙星(RO 23 - 6240)的体外活性比较
Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):63-6. doi: 10.1007/BF01962177.
9
Routes of quinolone permeation in Escherichia coli.喹诺酮在大肠杆菌中的渗透途径。
Antimicrob Agents Chemother. 1988 Apr;32(4):438-42. doi: 10.1128/AAC.32.4.438.
10
Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.三氟喹诺酮类药物氟罗沙星在人体中的单剂量和多剂量药代动力学。
Antimicrob Agents Chemother. 1987 Dec;31(12):1909-14. doi: 10.1128/AAC.31.12.1909.

本文引用的文献

1
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.蛋白质结合对六种β-内酰胺类抗生素组织液水平的影响。
J Infect Dis. 1980 Jul;142(1):77-82. doi: 10.1093/infdis/142.1.77.
2
Pharmacokinetics and tissue penetration of ciprofloxacin.环丙沙星的药代动力学及组织穿透性
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
3
The pharmacokinetics and tissue penetration of ofloxacin.氧氟沙星的药代动力学和组织穿透性。 (注:原文中多了一个of,正确表述应该是The pharmacokinetics and tissue penetration of ofloxacin )
J Antimicrob Chemother. 1984 Dec;14(6):647-52. doi: 10.1093/jac/14.6.647.
4
Pharmacokinetics and tissue penetration of enoxacin.依诺沙星的药代动力学和组织穿透性。
Antimicrob Agents Chemother. 1984 Jul;26(1):17-9. doi: 10.1128/AAC.26.1.17.
5
Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.甲磺酸培氟沙星在小鼠、大鼠、犬、猴及人体内的吸收、分布、代谢转归及消除
Antimicrob Agents Chemother. 1984 Apr;25(4):463-72. doi: 10.1128/AAC.25.4.463.
6
Norfloxacin disposition after sequentially increasing oral doses.依次增加口服剂量后诺氟沙星的处置情况。
Antimicrob Agents Chemother. 1983 Feb;23(2):284-8. doi: 10.1128/AAC.23.2.284.
7
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.新型二氟喹诺酮衍生物Ro 23 - 6240与其他抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1986 Aug;30(2):330-2. doi: 10.1128/AAC.30.2.330.
8
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.新型喹诺酮衍生物AM-833的体外和体内抗菌活性
Antimicrob Agents Chemother. 1986 Jun;29(6):1059-66. doi: 10.1128/AAC.29.6.1059.
9
Drug therapy. Clinical Pharmacokinetics (first of two parts).药物治疗。临床药代动力学(两部分中的第一部分)。
N Engl J Med. 1975 Oct 2;293(14):702-5. doi: 10.1056/NEJM197510022931406.